OPEN END TURBO OHNE STOP-LOSS - INNOCAN PHARMA | Market Closed - Börse Stuttgart 07:09:21 14/06/2024 BST | ||
| 0.083 EUR | -1.19% |
|
| Current month | -4.60% | ||
| 1 month | -6.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.083 | -1.19% |
| 13/06/24 | 0.084 | 0.00% |
| 12/06/24 | 0.084 | +2.44% |
| 11/06/24 | 0.082 | +3.80% |
| 10/06/24 | 0.079 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 07:09 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | INNOCAN PHARMA CORPORATION |
| Issuer | Lang & Schwarz |
| WKN | LX3B3Q |
| ISIN | DE000LX3B3Q9 |
| Date issued | 02/08/2023 |
| Strike | 0.12 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 0.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.22 € |
|---|---|
| Lowest since issue | 0.039 € |
Company Profile
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Sector
-
Consensus: InnoCan Pharma Corporation
Sell
Buy
Mean consensus
Number of Analysts
0
Last Close Price
0.27
Average target price
-
- Stock Market
- Certificates
- Certificat